Rezolute, Inc.
  • About Us
    • Mission
    • Leadership
    • Contact
  • Our Focus
    • Hyperinsulinism Therapeutics
    • Publications & Presentations
  • Our Pipeline
    • Development Pipeline
    • Ersodetug
    • Clinical Trials
  • Join Us
    • Our Culture
    • Job Openings
  • Investors & Media
    • Investors Overview
    • Corporate Presentation
    • Press Releases
    • Events
    • Stock Quote & Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Investor Contacts
  • for patients
    • Understanding Hyperinsulinism
    • Join the Rezolution
Skip to main content Skip to section navigation Skip to footer
Rezolute, Inc. IR Overview
  • chevron_leftBack to rezolutebio.com
  • Investors Overview
  • Corporate Presentation
  • Press Releases
  • Events
  • Stock Quote & Chart
  • Historical Data
  • Analyst Coverage
  • SEC Filings
  • Governance
    • Governance Documents
  • Investor Contacts

Press Releases

Investors

Investors

  • Investors Overview
  • Corporate Presentation
  • Press Releases
  • Events
  • Stock Quote & Chart
  • Historical Data
  • Analyst Coverage
  • SEC Filings
  • Governance
    • Governance Documents
  • Investor Contacts
Apr 19, 2021 8:00 am EDT
Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners
Mar 22, 2021 8:00 am EDT
Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
Mar 8, 2021 8:00 am EST
Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
Mar 2, 2021 5:16 pm EST
Rezolute to Participate in Upcoming Investor Conferences in March
Feb 10, 2021 4:05 pm EST
Rezolute Reports Second Quarter Fiscal 2021 Financial Results
Jan 12, 2021 8:30 am EST
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
Dec 28, 2020 4:05 pm EST
Rezolute Announces Change of Transfer Agent
Dec 3, 2020 8:00 am EST
FDA Clears Rezolute’s IND Application for RZ402
Nov 19, 2020 8:00 am EST
Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 5, 2020 8:00 am EST
Rezolute Announces Uplisting to the Nasdaq Capital Market
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • …
  • Page 17
  • Next Pagearrow_forward
rss_feed News RSS

Stay Connected

  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
Visit us on LinkedIn Visit us on X Visit us on Facebook
Footer logo

Join our passionate and dedicated team to make a difference for patients.

SEE OPEN JOBS
  • About Us
    • Mission
    • Leadership
    • Contact
  • Our Focus
    • Hyperinsulinism Therapeutics
    • Publications & Presentations
  • Our Pipeline
    • Development Pipeline
    • Ersodetug
    • Clinical Trials
  • Join Us
    • Our Culture
    • Job Openings
  • Investors & Media
    • Investors Overview
    • Corporate Presentation
    • Press Releases
    • Events
    • Stock Quote & Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Investor Contacts
  • for patients
    • Understanding Hyperinsulinism
    • Rezolution Community
©2025 Rezolute, Inc. All rights reserved. Privacy Policy Terms of Use
Made by 22 Fillmore